Eloxx Pharmaceuticals (NASDAQ:ELOX) Shares Down 1.8%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) traded down 1.8% during mid-day trading on Wednesday . The stock traded as low as $0.80 and last traded at $0.81. 1,251 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 9,554 shares. The stock had previously closed at $0.83.

Eloxx Pharmaceuticals Stock Performance

The company has a market capitalization of $2.53 million, a price-to-earnings ratio of -0.09 and a beta of 2.75. The firm’s 50-day simple moving average is $0.93 and its 200-day simple moving average is $1.12.

Institutional Trading of Eloxx Pharmaceuticals

A hedge fund recently bought a new stake in Eloxx Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) during the 3rd quarter, according to its most recent filing with the SEC. The fund bought 275,000 shares of the company’s stock, valued at approximately $1,323,000. Armistice Capital LLC owned approximately 10.00% of Eloxx Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.90% of the company’s stock.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations.